This phase II trial is evaluating an intravenous drug (prexasertib) in women with platinum-resistant or refractory recurrent ovarian cancer.
This trial is treating patients with Ovarian, Fallopian tube or Peritoneal Cancer.
This is a systemic therapy trial.
You may be able to join this trial if:
- You have had treatment but your cancer has gotten worse or has not responded to the treatment you have been given.
- You have had treatment, but your cancer has come back.
You may be excluded from this trial if:
- You have a certain disease or psychological condition.
- You have had certain treatments, surgical procedures or drugs.
Clinical trials have complex eligibility criteria - talk to your doctor about your interest in this trial.